FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226022978> ?p ?o ?g. }

• W4226022978 endingPage "1335" @default.
• W4226022978 startingPage "1327" @default.
• W4226022978 abstract "Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but the optimal dose remains unknown. Objectives: To characterize the association between isoniazid pharmacokinetics (standard or high dose) and early bactericidal activity against M. tuberculosis (drug sensitive and inhA mutated) and N-acetyltransferase 2 status. Methods: ACTG (AIDS Clinical Trial Group) A5312/INHindsight is a 7-day early bactericidal activity study with isoniazid at a normal dose (5 mg/kg) for patients with drug-sensitive bacteria and 5, 10, and 15 mg/kg doses for patients with inhA mutants. Participants with pulmonary tuberculosis received daily isoniazid monotherapy and collected sputum daily. Colony-forming units (cfu) on solid culture and time to positivity in liquid culture were jointly analyzed using nonlinear mixed-effects modeling. Measurements and Main Results: Fifty-nine adults were included in this analysis. A decline in sputum cfu was described by a one-compartment model, whereas an exponential bacterial growth model was used to interpret time-to-positivity data. The model found that bacterial kill is modulated by isoniazid concentration using an effect compartment and a sigmoidal Emax relationship (a model linking the drug concentration to the observed effect). The model predicted lower potency but similar maximum kill of isoniazid against inhA-mutated compared with drug-sensitive isolates. Based on simulations from the pharmacokinetics-pharmacodynamics model, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, 10- and 15-mg/kg doses are necessary against inhA-mutated isolates in slow and intermediate N-acetyltransferase 2 acetylators, respectively. Fast acetylators underperformed even at 15 mg/kg. Conclusions: Dosing of isoniazid based on N-acetyltransferase 2 acetylator status may help patients attain effective exposures against inhA-mutated isolates. Clinical trial registered with www.clinicaltrials.gov (NCT01936831)." @default.
• W4226022978 created "2022-05-05" @default.
• W4226022978 creator A5007514947 @default.
• W4226022978 creator A5020131744 @default.
• W4226022978 creator A5020952516 @default.
• W4226022978 creator A5028037547 @default.
• W4226022978 creator A5045831486 @default.
• W4226022978 creator A5045935529 @default.
• W4226022978 creator A5048965341 @default.
• W4226022978 creator A5051030842 @default.
• W4226022978 creator A5053945845 @default.
• W4226022978 creator A5056892721 @default.
• W4226022978 creator A5059434182 @default.
• W4226022978 creator A5060359856 @default.
• W4226022978 creator A5071465160 @default.
• W4226022978 creator A5075758950 @default.
• W4226022978 creator A5077848127 @default.
• W4226022978 creator A5085712485 @default.
• W4226022978 date "2021-12-01" @default.
• W4226022978 modified "2023-10-16" @default.
• W4226022978 title "A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial" @default.
• W4226022978 cites W1211808353 @default.
• W4226022978 cites W1414898727 @default.
• W4226022978 cites W1977756904 @default.
• W4226022978 cites W1986157879 @default.
• W4226022978 cites W1993312318 @default.
• W4226022978 cites W1993466757 @default.
• W4226022978 cites W2007102363 @default.
• W4226022978 cites W2019923476 @default.
• W4226022978 cites W2033228816 @default.
• W4226022978 cites W2035387023 @default.
• W4226022978 cites W2036391785 @default.
• W4226022978 cites W2081553615 @default.
• W4226022978 cites W2097465589 @default.
• W4226022978 cites W2105286312 @default.
• W4226022978 cites W2114698696 @default.
• W4226022978 cites W2120416054 @default.
• W4226022978 cites W2142127075 @default.
• W4226022978 cites W2152541723 @default.
• W4226022978 cites W2154005051 @default.
• W4226022978 cites W2161329013 @default.
• W4226022978 cites W2169835563 @default.
• W4226022978 cites W2327069149 @default.
• W4226022978 cites W2516060412 @default.
• W4226022978 cites W2557634135 @default.
• W4226022978 cites W2561635964 @default.
• W4226022978 cites W2569834008 @default.
• W4226022978 cites W2581216796 @default.
• W4226022978 cites W2770676136 @default.
• W4226022978 cites W2773907647 @default.
• W4226022978 cites W2776796604 @default.
• W4226022978 cites W2794372577 @default.
• W4226022978 cites W2802200589 @default.
• W4226022978 cites W2933620934 @default.
• W4226022978 cites W3005799566 @default.
• W4226022978 cites W3094407876 @default.
• W4226022978 cites W4205663644 @default.
• W4226022978 cites W4238048406 @default.
• W4226022978 doi "https://doi.org/10.1164/rccm.202103-0534oc" @default.
• W4226022978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34403326" @default.
• W4226022978 hasPublicationYear "2021" @default.
• W4226022978 type Work @default.
• W4226022978 citedByCount "12" @default.
• W4226022978 countsByYear W42260229782022 @default.
• W4226022978 countsByYear W42260229782023 @default.
• W4226022978 crossrefType "journal-article" @default.
• W4226022978 hasAuthorship W4226022978A5007514947 @default.
• W4226022978 hasAuthorship W4226022978A5020131744 @default.
• W4226022978 hasAuthorship W4226022978A5020952516 @default.
• W4226022978 hasAuthorship W4226022978A5028037547 @default.
• W4226022978 hasAuthorship W4226022978A5045831486 @default.
• W4226022978 hasAuthorship W4226022978A5045935529 @default.
• W4226022978 hasAuthorship W4226022978A5048965341 @default.
• W4226022978 hasAuthorship W4226022978A5051030842 @default.
• W4226022978 hasAuthorship W4226022978A5053945845 @default.
• W4226022978 hasAuthorship W4226022978A5056892721 @default.
• W4226022978 hasAuthorship W4226022978A5059434182 @default.
• W4226022978 hasAuthorship W4226022978A5060359856 @default.
• W4226022978 hasAuthorship W4226022978A5071465160 @default.
• W4226022978 hasAuthorship W4226022978A5075758950 @default.
• W4226022978 hasAuthorship W4226022978A5077848127 @default.
• W4226022978 hasAuthorship W4226022978A5085712485 @default.
• W4226022978 hasBestOaLocation W42260229782 @default.
• W4226022978 hasConcept C111113717 @default.
• W4226022978 hasConcept C112705442 @default.
• W4226022978 hasConcept C114851261 @default.
• W4226022978 hasConcept C142724271 @default.
• W4226022978 hasConcept C2776301714 @default.
• W4226022978 hasConcept C2776967927 @default.
• W4226022978 hasConcept C2777975735 @default.
• W4226022978 hasConcept C2780687663 @default.
• W4226022978 hasConcept C2781069245 @default.
• W4226022978 hasConcept C71924100 @default.
• W4226022978 hasConcept C86803240 @default.
• W4226022978 hasConcept C89423630 @default.
• W4226022978 hasConcept C98274493 @default.
• W4226022978 hasConceptScore W4226022978C111113717 @default.
• W4226022978 hasConceptScore W4226022978C112705442 @default.

• next